Arcutis Biotherapeutics, Inc. (ARQT)
25.55
-1.45
(-5.37%)
USD |
NASDAQ |
Nov 06, 16:00
25.56
+0.01
(+0.04%)
After-Hours: 20:00
Arcutis Biotherapeutics Research and Development Expense (Quarterly) : 22.42M for Sept. 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 22.42M |
| June 30, 2026 | 20.36M |
| March 31, 2026 | 30.63M |
| December 31, 2025 | 20.45M |
| September 30, 2025 | 19.60M |
| June 30, 2025 | 19.45M |
| March 31, 2025 | 17.54M |
| December 31, 2024 | 14.48M |
| September 30, 2024 | 19.50M |
| June 30, 2024 | 19.30M |
| March 31, 2024 | 23.14M |
| December 31, 2023 | 23.78M |
| September 30, 2023 | 26.24M |
| June 30, 2023 | 25.22M |
| March 31, 2023 | 35.34M |
| December 31, 2022 | 33.88M |
| September 30, 2022 | 69.73M |
| Date | Value |
|---|---|
| June 30, 2022 | 38.20M |
| March 31, 2022 | 40.62M |
| December 31, 2021 | 52.56M |
| September 30, 2021 | 40.60M |
| June 30, 2021 | 30.76M |
| March 31, 2021 | 21.63M |
| December 31, 2020 | 27.37M |
| September 30, 2020 | 32.74M |
| June 30, 2020 | 30.01M |
| March 31, 2020 | 25.18M |
| December 31, 2019 | 10.76M |
| September 30, 2019 | 12.35M |
| June 30, 2019 | 7.213M |
| March 31, 2019 | 6.203M |
| December 31, 2018 | 5.347M |
| September 30, 2018 | 7.081M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 76.28M |
| ADMA Biologics, Inc. | 4.49M |
| Alnylam Pharmaceuticals, Inc. | 408.54M |
| Anika Therapeutics, Inc. | 7.895M |
| Savara, Inc. | 21.95M |